NCT05815342Completed
OP5-005 Using Omnipod 5 in Adults With Type 2
Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 29 Sept 2025
Brief summary (registry, in English)
This is a single arm, multi-center, prospective study that will evaluate the safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes requiring insulin therapy.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 343 (actual)
- First submitted
- 21 Mar 2023
- Start date
- Apr 2023
- Primary completion date
- Mar 2024
- Lead sponsor
- Insulet Corporation
- Diseases
- Type 2 diabetes
- NCT number
- NCT05815342
What you commit to
- Study type: Interventional
- Participants enrolled: 343
- From Apr 2023 to the primary completion date, Mar 2024
- 21 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of an AID pump in automated mode within 3 months prior to screening
- Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
- Any planned surgery during the study which could be considered major in the opinion of the investigator
- History of more than 1 severe hypoglycemic event in the 6 months prior to screening
- History of more than 1 episode of diabetic ketoacidosis (DKA) or Hyperosmolar hyperglycemic syndrome (HHS) in the 6 months prior to screening; unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis
- Has taken oral or injectable steroids within 8 weeks prior to screening or plans to take oral or injectable steroids during the study
- Pregnant or lactating, planning to become pregnant during the study, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal)
- Participation in another clinical study using an investigational drug or device other than the Omnipod 5 in the 30 days prior to screening or intends to participate during the study period
Other illness
- Any medical condition which in the opinion of the investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and/or eating disorders (i.e. anorexia/bulimia)
- Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement
Lab values
- Blood disorder or dyscrasia within 3 months prior to screening, including use of hydroxyurea, which in the investigator's opinion could interfere with determination of HbA1c
Other
- Plans to receive blood transfusion over the course of the study
- Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment
- Participant is an employee of Insulet, an Investigator or Investigator's study team, or immediate family member (spouse, biological or legal guardian, child, sibling, parent) of any of the aforementioned
Who the study is looking for
- Age at time of consent 18-75 years
- Diagnosed with type 2 diabetes, on current insulin regimen for at least 3 months prior to screening (i.e. Basal-bolus, basal only or pre-mix)
- Basal bolus (long-acting insulin and rapid acting analog) or pre-mix users with A1C \<12.0% OR basal users on long or intermediate acting insulin only with A1C \> 7.0% and \< 12.0%
- Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, or Admelog
- Participant agrees to provide their own insulin for the duration of the study
- Stable doses over the preceding 4 weeks of other glucose-lowering medications as determined by Investigator
- Stable doses of weight loss medications over the preceding 4 weeks and throughout the study that may affect glycemic control directly and/or indirectly, except for a dose reduction or discontinuation, as determined by Investigator
- Willing to wear the system continuously throughout the study
- Deemed appropriate for pump therapy per investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
- Investigator has confidence that the participant has the cognitive ability and can successfully operate all study devices and can adhere to the protocol
- Able to read and understand English or Spanish
- Willing and able to sign the Informed Consent Form (ICF)
- If female of childbearing potential, willing and able to have pregnancy testing
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (21)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MAHEC Coordinator of this site? Confirm its status | Asheville | United States | Unknown status |
| Emory Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| University of Colorado Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
| Texas Diabetes and Endocrinology Coordinator of this site? Confirm its status | Austin | United States | Unknown status |
| Joslin Diabetes Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| East Coast Institute for Research Coordinator of this site? Confirm its status | Canton | United States | Unknown status |
| University of North Carolina Coordinator of this site? Confirm its status | Chapel Hill | United States | Unknown status |
| University Diabetes and Endocrine Consultants Coordinator of this site? Confirm its status | Chattanooga | United States | Unknown status |
| Ohio State Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
| Henry Ford Coordinator of this site? Confirm its status | Detroit | United States | Unknown status |
| Diabetes and Thyroid Center Coordinator of this site? Confirm its status | Fort Worth | United States | Unknown status |
| Physicians East Coordinator of this site? Confirm its status | Greenville | United States | Unknown status |
| East Coast Institute for Research Coordinator of this site? Confirm its status | Jacksonville | United States | Unknown status |
| University of Southern California Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| Health Partners Coordinator of this site? Confirm its status | Minneapolis | United States | Unknown status |
| Endocrine Research Coordinator of this site? Confirm its status | Roswell | United States | Unknown status |
| Diabetes and Glandular Disease Clinic Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
| Sansum Diabetes Research Institute Coordinator of this site? Confirm its status | Santa Barbara | United States | Unknown status |
| Albert Einstein College of Medicine Coordinator of this site? Confirm its status | The Bronx | United States | Unknown status |
| Metabolic Research Institute Coordinator of this site? Confirm its status | West Palm Beach | United States | Unknown status |
| Accellacare Coordinator of this site? Confirm its status | Wilmington | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.